Fleming Christina, Baker Joseph F, O'Neill Shane C, Rowan Fiachra E, Byrne Damien P, Synnott Keith
Department of Orthopaedic Surgery, Mater Misericordiae University Hospital, Dublin, Ireland.
Department of Orthopaedic Surgery, Galway University Hospital, Galway, Ireland.
Eur Spine J. 2016 Jan;25(1):252-256. doi: 10.1007/s00586-014-3730-z. Epub 2014 Dec 25.
The Oswestry Spinal Risk Index (OSRI) was recently reported as an adjunct in the management of metastatic spinal disease. Based on the tumour type and a general condition score, survivorship is predicted. We aimed to externally validate this new score.
We assessed the survivorship of 121 patients identified from a prospectively collated database in the National Spinal Injuries Unit in the Republic of Ireland. Actual survivorship was calculated according to the tumour subtype and general conditioning, according to the Karnofsky Performance Score (OSRI = Primary Tumour Pathology + (2-General Conditioning Score)). Our results were then compared to those previously published.
45.5 % were female (n = 55). The mean age at presentation was 61.5 years (range 23-85). Breast and prostate cancers were the most frequent diseases encountered. The actual survival in our cohort closely mirrored the predicted survival, according to the equation used to calculate the OSRI with an overall strong correlation found (r = 0.798, p = 0.001).
We found that the OSRI is a simple to use scoring system. We found a strong correlation in our results with the predicted survivorship based on the OSRI. The OSRI can be used as a useful adjunct in the management of patient with metastatic disease of the spine.
最近有报道称奥斯维斯特里脊柱风险指数（OSRI）可作为转移性脊柱疾病管理的辅助工具。基于肿瘤类型和一般状况评分来预测生存期。我们旨在对这个新评分进行外部验证。
我们评估了从爱尔兰共和国国家脊髓损伤单位前瞻性整理的数据库中识别出的121例患者的生存期。根据肿瘤亚型和一般状况，按照卡诺夫斯基表现评分（OSRI = 原发性肿瘤病理 + （2 - 一般状况评分））计算实际生存期。然后将我们的结果与之前发表的结果进行比较。
45.5%为女性（n = 55）。就诊时的平均年龄为61.5岁（范围23 - 85岁）。乳腺癌和前列腺癌是最常见的疾病。根据用于计算OSRI的公式，我们队列中的实际生存期与预测生存期密切相符，发现总体相关性很强（r = 0.798，p = 0.001）。
我们发现OSRI是一个易于使用的评分系统。我们的结果与基于OSRI预测的生存期有很强的相关性。OSRI可作为脊柱转移性疾病患者管理中的有用辅助工具。
